Atrys Health (XMAD:ATRY) Asset Impairment Charge: €0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:ATRY Atrys Health SA XMAD:ATRY
63 GF Score
Price €2.50
GF Value €3.25
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health Asset Impairment Charge?

Atrys Health XMAD:ATRY -0.79% 63 Asset Impairment Charge is €0.0 Mil as of Dec. 2025. GuruFocus rates XMAD:ATRY with a GF Score™ of 63/100 and a GF Value™ of €3.25 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Atrys Health's Asset Impairment Charge for the six months ended in Dec. 2025 was €0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Atrys Health Asset Impairment Charge Related Terms

Atrys Health Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Atrys Health's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrys Health Asset Impairment Charge Chart

Atrys Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Atrys Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XMAD:ATRY
63GF Score
Atrys Health SA XMAD:ATRY
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrys Health Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

What does a Asset Impairment Charge of €0.0 Mil mean?
Atrys Health (XMAD:ATRY) has a Asset Impairment Charge of €0.0 Mil as of Dec. 2025.
Is Atrys Health's Asset Impairment Charge too high?
Atrys Health's current Asset Impairment Charge is €0.0 Mil. Overall, Atrys Health has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Asset Impairment Charge compare to VRTX and REGN?
Atrys Health's Asset Impairment Charge of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Biotechnology company?
A good Asset Impairment Charge depends on the Biotechnology industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Atrys Health's current Asset Impairment Charge is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.25, compared to a current price of €2.50 — trading 23.1% below its estimated fair value. The current Asset Impairment Charge is €0.0 Mil. Atrys Health's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Asset Impairment Charge is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.50 is trading 23.1% below its estimated GF Value™ of €3.25. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • Asset Impairment Charge: €0.0 Mil
  • GF Value™: €3.25 vs. price of €2.50 (23.1% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
63GF Score

Get the complete analysis for XMAD:ATRY

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.50
Price
€3.25
GF Value